Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net loss $ (12,400) $ (11,813)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 523 646
Stock-based compensation 994 491
Non-cash interest expense 346 246
Change in fair value of preferred stock warrant liability 766
Non-cash portion of loss on debt extinguishment 161
Forgiveness of PPP loan (2,180)  
Deferred rent 355 (157)
Changes in operating assets and liabilities:    
Accounts receivable (2,849) (271)
Prepaid expenses and other current assets 502 44
Security Deposits 104  
Accounts payable 942 (361)
Accrued expenses and other current liabilities 229 454
Deferred revenue 269 (344)
Customer Deposits (306)  
Net cash used in operating activities (13,310) (10,299)
Cash flows from investing activities:    
Purchase of property and equipment (423) (427)
Net cash used in investing activities (423) (427)
Cash flows from financing activities:    
Proceeds from loan 15,000
Payment to unaccredited investors of Augmedix Operating Corporation (22)
Repayment of notes payable (12,966)
Proceeds of notes payable 2,180
Proceeds from issuance of convertible notes payable 500
Payment of financing costs (232) (129)
Payment of offering costs in relation to equity issuance (16)  
Proceeds from exercise of common stock warrants 4
Proceeds from exercise of stock options 113 2
Net cash provided by financing activities 1,881 2,553
Effect of exchange rate changes on cash and restricted cash (3) (1)
Net decrease in cash and restricted cash (11,855) (8,174)
Cash and restricted cash at beginning of period 22,973 11,603
Cash and restricted cash at end of period 11,118 3,429
Supplemental disclosure of cash flow information:    
Cash paid during the period for interest 1,290 942
Supplemental schedule of non-cash investing and financing activities:    
Deferred offering costs in accounts payable and accrued expenses 192 810
Fair value of warrants issued in connection with loan 395
Fair value of common stock issued to service provider 600  
Property, plant, and equipment in accounts payable $ 83